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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids was requested to
evaluate N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] in the Flavouring
Group Evaluation 302, using the Procedure in Commission Regulation (EC) No 1565/2000. The substance
is intended to be used as a ﬂavour modiﬁer and the current evaluation is only applicable to this use.
Information on the ratios of diastereoisomers of the substance has been provided (cis 20–40% and trans
60–80%). Information on the ratio of enantiomers is lacking. The available data on genotoxicity do not
preclude the evaluation of the candidate substance [FL-no: 16.119] through the Procedure. The
substance was evaluated through the B-side of the Procedure. A ‘No Observed Adverse Effect Level’
(NOAEL) of 55 mg/kg body weight (bw) per day could be derived for [FL-no: 16.119] from a 90-day
subchronic toxicity study in rats. This NOAEL provides an adequate margin of safety of 1.4 9 106, based
on the ‘Maximised Survey-Derived Daily Intake’ (MSDI) of 2.4 lg/capita per day. Based on the ‘modiﬁed
Theoretical Added Maximum Daily Intake’ (mTAMDI) approach, the Panel concluded that more
information is needed on use and use levels. Besides the safety assessment of this ﬂavouring substance,
the speciﬁcations for the material of commerce have also been considered. Additional information on the
stereoisomeric composition of the ﬂavouring substance is required.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The use of ﬂavourings in food is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20081 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list includes ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
During its 16th plenary meeting of 28–30 September 2010, the EFSA Scientiﬁc Panel on Food Contact
Materials, Enzymes, Flavourings and Processing Aids (CEF) decided to put the evaluation of the ﬂavouring
substance N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] from Flavouring
Group Evaluation 302 (FGE.302) on hold as the data available were not considered to be sufﬁcient for an
evaluation: no adequate toxicity study was available, from which a No Observed Adverse Effect Level
(NOAEL) could be established, neither for the substance itself nor for any structurally related substance.
The Panel concluded that the safety of the substance, when used as a ﬂavouring substance, could
therefore not be assessed and requested additional data, which would include absorption, distribution,
metabolism, elimination (ADME) data and an extended 90-day study, including endpoints on
reprotoxicity.
On 18 November 2013, the applicant submitted data on N-(2-methylcyclohexyl)-2,3,4,5,6-
pentaﬂuoro-benzamide [FL-no: 16.119].
Terms of Reference as provided by the European Commission
The European Commission requests the European Food Safety Authority (EFSA) to ﬁnalise its safety
assessment on this ﬂavouring substance in accordance with Commission Regulation (EC) No 1565/2000.
Interpretation of the Terms of Reference
The present scientiﬁc opinion FGE.302 covers the safety assessment of the following ﬂavouring
substance: N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL 16.119]. This substance will
be evaluated as a ﬂavour-modifying substance (cf. Regulation (EC) No 1334/2008 for concentrations
up to 5 mg/kg in solution (Dewis et al., 2009). Although [FL-no: 16.119] has also been reported to be
added to food as a sweetener and ﬂavour enhancer4 (Dewis et al., 2009), these uses are out of the
scope of the present evaluation which only assess the use of the substance as a ﬂavour modiﬁer. Use
as a sweetener or a ﬂavour enhancer would fall under the food additive legislation5 which has different
data requirements for safety evaluation.
2. Assessment
2.1. Presentation of the substances in Flavouring Group Evaluation 302
2.1.1. Description
The present FGE.302, using the procedure as referred to in the Commission Regulation (EC)
No 1565/2000 (The Procedure – shown in schematic form in Appendix A), deals with the safety
evaluation of the ﬂavouring substance N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [Fl-no:
16.119] from chemical group 30, Annex I of Commission Regulation (EC) No 1565/20003. The
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
4 http://www.thegoodscentscompany.com/data/rw1119821.html
5 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16–33.
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ﬂavouring substance (candidate substance) under consideration, as well as the chemical name,
FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract
Manufactures Association- (FEMA-) numbers, structure and speciﬁcations, are listed in Table 1.
N-(2-Methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] has been previously
evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) as of no safety concern
(JECFA, 2012). However, this evaluation was based on a NOAEL issued from a 28-day study in rats.
Currently, a 90-day study has become available and evaluated in the present FGE.
According to publically available information4 and Dewis et al. (2009), [Fl-no: 16.119] can be used
as a sweetener or as a ﬂavour enhancer. In addition, the substance can also be used as a ﬂavour
modiﬁer at concentrations up to 5 mg/kg in solutions. This opinion concerns only the safety of the
latter use.
No sufﬁciently structurally related substances were identiﬁed.
2.1.2. Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties.
Their ﬂavour may be different; they may have different chemical properties resulting in possible
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information
must be provided on the conﬁguration of the ﬂavouring substance, i.e. whether it is one of the
geometrical/optical isomers, or a deﬁned mixture of stereoisomers. The available speciﬁcations of
purity will be considered in order to determine whether the safety evaluation carried out for a
candidate substance for which stereoisomers may exist, can be applied to the material of commerce.
Flavouring substances with different conﬁgurations should have individual chemical names and codes
(CAS number, FLAVIS number, etc.).
The candidate substance belongs to structural class III. It possesses two chiral centres. Information
on the ratios of the diastereoisomers has been provided (cis 20–40% and trans 60–80%) (Flavour
Industry, 2015). Information on the ratio of enantiomers is lacking.
2.1.3. Natural occurrence in food
The candidate substance [FL-no: 16.119] has not been reported to occur naturally in food
(Triskelion, 2016).
2.2. Speciﬁcations
Purity criteria for the candidate substance N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide
[FL-no: 16.119] have been provided by the ﬂavour industry (Flavour Industry, 2009, 2015) (Table 1).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/20003,
information on the ratios of the diastereoisomers has been provided (cis 20–40% and trans 60–80%)
(Flavour Industry, 2015). Information on the ratio of enantiomers is lacking.
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2.3. Intake data
Annual production volumes of the ﬂavouring substance as surveyed by the ﬂavour industry can be
used to calculate the ‘Maximised Survey-derived Daily Intake’ (MSDI) by assuming that the production
ﬁgure only represents 60% of the use in food due to underreporting and that 10% of the total
European Union (EU) population are consumers (SCF, 1999).
However, the Panel noted that due to year-to-year variability in production volumes, to
uncertainties in the underreporting correction factor and to uncertainties in the percentage of
consumers, the reliability of intake estimates on the basis of the MSDI approach is difﬁcult to assess.
The Panel also noted that in contrast to the generally low per capita intake ﬁgures estimated on the
basis of this MSDI approach, in some cases the regular consumption of products ﬂavoured at use
levels reported by the ﬂavour industry in the submissions would result in much higher intakes. In such
cases, the human exposure thresholds below which exposures are not considered to present a safety
concern might be exceeded.
Considering that the MSDI model may underestimate the intake of a ﬂavouring substance by
certain groups of consumers, the Scientiﬁc Committee on Food (SCF) recommended also taking into
account the results of other intake assessments (SCF, 1999).
One of the alternatives is the ‘Theoretical Added Maximum Daily Intake’ (TAMDI) approach, which
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for ﬂavourable
beverages and foods in general, with exceptional levels for particular foods. This method is regarded
as a conservative estimate of the actual intake by most consumers because it is based on the
assumption that the consumer regularly eats and drinks several food products containing the same
ﬂavouring substance at the upper use level.
One option to modify the TAMDI approach is to base the calculation on normal rather than upper
use levels of the ﬂavouring substance. This modiﬁed approach is less conservative (e.g. it may
underestimate the intake of consumers being loyal to products ﬂavoured at the maximum use levels
reported). However, it is considered as a suitable tool to screen and prioritise the ﬂavouring substances
according to the need for reﬁned intake data (EFSA, 2004).
2.3.1. Estimated daily per capita intake (MSDI approach)
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the
amounts used in food as ﬂavourings (SCF, 1999). These data are derived from surveys on annual
production volumes in Europe. These surveys were conducted in 1995 by the International
Organization of the ﬂavour industry (IOFI), in which ﬂavour manufacturers reported the total amount
of each ﬂavouring substance incorporated into food sold in the EU during the previous year
(IOFI, 1995). The intake approach does not consider the possible natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is
consumed by 10% of the population6 (Eurostat, 1998). This is derived for candidate substances from
estimates of annual volume of production provided by the ﬂavour industry and incorporates a
correction factor of 0.6 to allow for incomplete reporting (60%) in the ﬂavour industry surveys
(SCF, 1999).
The anticipated total annual volume of production of the candidate substance in the present
Flavouring Group Evaluation (FGE.302) from use as ﬂavouring substance in Europe has been reported
to be approximately 20 kg (Flavour Industry, 2009). The daily per capita intake for the substance is
2.4 lg/capita per day (Table 3).
2.3.2. Intake estimated on the basis of the modiﬁed TAMDI (mTAMDI)
The method for calculation of modiﬁed TAMDI (mTAMDI) values is based on the approach used by
SCF up to 1995 (SCF, 1995).
The assumption is that a person may consume a certain amount of ﬂavourable foods and
beverages per day.
6 EU ﬁgures 375 million. This ﬁgure relates to EU population at the time for which production data are available, and is
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for
the enlarged EU (Eurostat, 1998).
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For the candidate substance information on food categories and normal and maximum use levels7,8
were submitted by the ﬂavour industry (Flavour Industry, 2014). The candidate substance is used in
ﬂavoured food products divided into the food categories, outlined in Annex III of the Commission
Regulation (EC) No 1565/20003, as shown in Table 2. For the present calculation of mTAMDI, the
reported normal use levels were used. In the case where different use levels were reported for
different food categories, the highest reported normal use level was used.
According to the ﬂavour industry, the normal use levels for the candidate substance are in the
range of 1–5 mg/kg food, and the maximum use levels are in the range of 2–25 mg/kg (Flavour
Industry, 2014).
The mTAMDI value is 520 lg/person per day for the candidate substance from structural class III
(see Section 6).
For detailed information on use levels and intake estimations based on the mTAMDI approach, see
Appendix C.
3. Absorption, distribution, metabolism and elimination
The kinetics of the candidate substance have been investigated in microsomes, in hepatocytes and
in vivo by autoradiography (14C incorporated on the carbonyl group) after a single oral administration
to rats.
Results from the in vitro study on metabolism in rat liver microsomes show that 14C radiolabelled
N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide is readily hydroxylated in liver microsomes
incubated with NADPH generating system as a co-factor. These metabolites may be anticipated to be
easily conjugated and excreted.
Also, in suspension cultures of cryopreserved hepatocytes incubated with [FL-no: 16.119], rapid
metabolism of the candidate ﬂavouring substance was observed but no attempt was made to identify
Table 2: Use of the candidate substance
Food category Description Flavouring used
01.0 Dairy products, excluding products of category 2 Yes
02.0 Fats and oils, and fat emulsions (type water-in-oil) No
03.0 Edible ices, including sherbet and sorbet Yes
04.1 Processed fruits Yes
04.2 Processed vegetables (including mushrooms & fungi, roots &
tubers, pulses and legumes), and nuts & seeds
Yes
05.0 Confectionery Yes
06.0 Cereals and cereal products, including ﬂours & starches from
roots & tubers, pulses & legumes, excluding bakery
No
07.0 Bakery wares Yes
08.0 Meat and meat products, including poultry and game No
09.0 Fish and ﬁsh products, including molluscs, crustaceans and
echinoderms
No
10.0 Eggs and egg products No
11.0 Sweeteners, including honey No
12.0 Salts, spices, soups, sauces, salads, protein products etc. No
13.0 Foodstuffs intended for particular nutritional uses No
14.1 Non-alcoholic (‘soft’) beverages, excluding dairy products Yes
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic
counterparts
No
15.0 Ready-to-eat savouries No
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods
that could not be placed in categories 1–15
No
7 ‘Normal use’ is deﬁned as the average of reported usages and ‘maximum use’ is deﬁned as the 95th percentile of reported
usages (EFFA, 2002).
8 The normal and maximum use levels in different food categories have been extrapolated from ﬁgures derived from 12 model
ﬂavouring substances (EFFA, 2004).
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the biotransformation products. Next to hydroxylation, hydrolysis of the amide bond might occur which
would result in formation of 2-methyl-cyclohexylamine and pentaﬂuorobenzoic acid. However, there are
no experimental data to support this. In addition, there is no information whether deﬂuorination
in vivo might occur but from the molecular structure this seems unlikely.
In the autoradiography study, there was still radioactivity in tissues 72 hours after dosage but the
studies do not suggest retention in a speciﬁc organ and indicate an efﬁcient elimination within the
observation period.
Some perﬂuorinated alkyl substances are bioaccumulative (EFSA, 2008; EFSA CEF Panel, 2010).
Although the candidate substance is not a perﬂuorinated alkyl substance, the presence of a perﬂuorinated
aryl moiety might suggest a potential bioaccumulation. However, the above described experimental data
indicate that for N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide bioaccumulation is not of
concern.
From the available information, it is not possible to conclude how the candidate substance will be
metabolised in vivo. Therefore, it cannot be anticipated that the candidate substance [FL-no: 16.119]
will be metabolised to innocuous products.
For more detailed information, see Appendix D.
4. Application of the Procedure for the safety evaluation of ﬂavouring
substances
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a ﬂavouring substance might exceed its
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure.
In these cases, the Panel requires more precise data on use and use levels. For comparison of the
intake estimations based on the MSDI approach and the mTAMDI approach, see Section 5.
For the safety evaluation of the candidate substance from chemical group 30, the Procedure as
outlined in Appendix A was applied, based on the MSDI approach. The stepwise evaluation of the
substance is summarised on Figure A.1 and Table B.1.
Step 1
The candidate substance N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119]
is classiﬁed into structural class III according to the decision tree approach by Cramer et al. (1978).
Step 2
Step 2 requires consideration of the metabolism of the candidate substances. The candidate
substance [FL-no: 16.119] cannot be anticipated to be metabolised to innocuous products and thus
the evaluation proceeds via the B-side of the Procedure scheme.
Step B3
The estimated daily per capita intake of the candidate substances [FL-no: 16.119] is 2.4 lg, which
is below the threshold for its structural class of 90 lg/person per day (class III). Accordingly, the
evaluation of the substance proceeds to step B4 of the Procedure.
Step B4
A NOAEL of 55 mg/kg bw per day may be derived from a 90-day study providing an adequate
margin of safety of 1.4 9 106. Thus, it can be concluded that N-(2-methylcyclohexyl)-2,3,4,5,6-
pentaﬂuoro-benzamide [FL-no: 16.119] is not of safety concern at the estimated levels of intake based
on the MSDI approach.
5. Comparison of the intake estimations based on the MSDI approach
and the mTAMDI approach
The estimated intake of the candidate substance [FL-no: 16.119] assigned to structural class III,
based on the mTAMDI, is 520 lg/person per day, which is above the threshold of concern for
structural class III of 90 lg/person per day.
Thus, for the candidate substances [FL-no: 16.119], further information is required. This would
include more reliable intake data and then, if required, additional toxicological data.
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach,
see Table 3.
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6. Considerations of combined intakes from use as ﬂavouring
substances
Combined intake is not relevant as this FGE concerns only one candidate substance and no
structurally related substances were available.
7. Toxicity
7.1. Acute toxicity
No data on acute toxicity have been submitted, and no data on acute toxicity of the candidate
substance [FL-no: 16.119] were found when a literature search was conducted.
7.2. Subacute, subchronic, chronic and carcinogenicity studies
N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119]
28-day feeding toxicity study in rats
A 28-day feeding study in rats was conducted for the candidate substance N-(2-methylcyclohexyl)-
2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] at doses of 0, 750, 1,500 and 3,000 mg/kg which
correspond to dose levels of 0, 67, 130 and 262 mg/kg bw per day, respectively. The control group
and each dosage group consisted of ﬁve female and ﬁve male rats.
In all dosage groups, reduction in mobile activity was noted; however, evidence of neurotoxicity
was absent. A reduction in body weight gain was observed in the highest dose group, which was
statistically signiﬁcant for males but not for females. In the high-dose animals, a reduction in food
efﬁciency was noted during part of the study time. Males in the highest dose group showed reduction
in red blood cell count, increases in neutrophil counts and increase in alkaline phosphatase, which
were statistically signiﬁcant. Females in the highest dose group demonstrated statistically signiﬁcant
increases in total protein, albumin and total cholesterol; they also showed reduction in absolute spleen
weights and increase in relative spleen weights. In males from the two highest dosage groups,
increase in activated partial thromboplastin time was observed. In all female treatment groups, a
statistically signiﬁcant increase in absolute and relative liver weights were noted, but without dose–
response. No histopathological changes were observed (Dunster, 2009).
90-day subchronic toxicity study in rats
A 90-day dietary study was performed with N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-
benzamide [FL-no: 16.119] (Bauter, 2013) according to OECD guideline (TG 408) and the requirements
of US FDA Good Laboratory Practice (GLP) Standards.
Four groups (10/sex per dietary intake level) of male and female CRL Wistar Han IGS rats were fed
a diet that contained 0 (dietary control), 750 (low-dose group), 1,500 (mid-dose group) or 3,000
(high-dose group) mg/kg N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide. The levels
corresponded to a calculated daily intake of 0, 55, 108 and 218 mg/kg bw, respectively, for males and
0, 66, 125 or 255 mg/kg bw, respectively, for females. Stability of the test substance under storage
conditions as well as the stability of the test substance in the feed matrix was found to be adequate.
Blood samples for haematology and clinical chemistry analysis were drawn on days 43 and 85 of the
study. Urine samples were also collected on days 43 and 85. All animals survived the course of the
study, and were sacriﬁced on day 93. Material from ca 40 tissues/locations was collected and
preserved for all animals. However, only tissues from the control and high-dose groups were fully
examined. For the low- and mid-dose groups only tissues for which in the high-dose group an effect
Table 3: Estimated intakes based on the MSDI approach and the mTAMDI approach
FL-no EU Register name
MSDI
(lg/capita
per day)
mTAMDI
(lg/person
per day)
Structural
class
Threshold of
concern (lg/person
per day)
16.119 N-(2-Methylcyclohexyl)-2,3,4,5,
6-pentaﬂuoro-benzamide
2.4 520 Class III 90
MSDI: Maximised Survey-derived Daily Intake; mTAMDI: modiﬁed Theoretical Added Maximum Daily Intake.
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was observed, tissues with gross lesions and all sex organs were analysed. A neurobehavioural
functional observational battery was not included in the study design.
Analysis of plasma was made for the parent compound and a putative hydroxymetabolite was
performed for all groups. Trace levels of the parent and/or putative hydroxymetabolite were detected
in all three groups receiving the test substance. Limit of quantiﬁcation was 1 ng/mL (ppb). Measured
concentrations ranged from 1 to 4.94 ng/mL, with the highest value for the putative metabolite in the
plasma of an animal in the high-dose group.
Clinical signs attributed to the test substance were a dietary concentration dependent increase in
severity of whitening of the teeth, which was noted for the mid- and high-dose groups, beginning on
day 36 and continuing throughout the course of the study. Three high-dose group males had broken
upper incisor teeth days 42–93, which was potentially attributed to the observed enamel degeneration.
Clinical examination did not reveal indications of behavioural changes (e.g. changes in gait, posture, and
response to handling, as well as the presence of clonic or tonic movements), stereotypies (e.g. excessive
grooming, repetitive circling) or bizarre behaviour (e.g. self-mutilation, walking backwards).
Decreased body weight and body weight gain in the high-dose group males and females were
attributed to decreased food intake, related to the test substance at high levels and considered
non-adverse.
Statistically signiﬁcant differences (p < 0.05) in haematology parameters for male rats included
decreased monocyte concentration in the mid-dose group on day 43, and decreased neutrophil and
eosinophil concentration in the mid-dose group on day 85 and increased large unstained cell
concentration in the high-dose group on day 85. Female rats showed statistically signiﬁcant (p < 0.05)
decreased red blood cell concentration in the high-dose group on day 43, and decreased haemoglobin
and haematocrit in the mid- and high-dose groups on days 43 and 85.
Statistically signiﬁcant differences (p < 0.05) that were measured for clinical chemistry parameters
included dose-dependent decreased serum alanine aminotransferase which was signiﬁcant in high-dose
males at days 43 and 85 and in high-dose females at day 43. Male rats in the high-dose group had
signiﬁcantly decreased sorbitol dehydrogenase levels days 43 and 85, the same dose-dependent
tendency was found in females although not signiﬁcant. Blood glucose showed a dose-dependent
decrease and was signiﬁcantly lowered in high-dose males at day 85 and in mid- and high-dose
females on day 85. A dose-dependent increase in serum inorganic phosphorous levels was apparent in
both male and female rats; signiﬁcantly increased levels were measured in high-dose males on day 43
and in both mid- and high-dose males on day 85.
Analysis of urine showed signiﬁcantly increased urine volume for males in the high-dose group at
day 85, and reduced speciﬁc gravity and reduced urinary protein at days 43 and 85 (p < 0.05 except
for urinary protein day 85 where p < 0.002). For these three parameters, the changes were dose-
dependent and were apparent also in females, although not statistically signiﬁcant.
Histopathology ﬁndings of note were degeneration of teeth in the nose/nasal turbinate sections of
all animals, males and females, in the high-dose group. Findings included disorganisation of the
ameloblast layer, accompanied by irregular deposits of enamel and less dentin in each affected tooth.
The teeth were misshaped. These ﬁndings correspond to the concentration-dependent whitening of
the teeth in the mid- and high-dose groups that were apparent from day 36 and onwards, and also
with the broken upper incisor teeth during the latter part of the study that occurred in three males in
the high-dose group. No alterations were observed in the rats molar teeth. However, the Panel noted
that the use of the rat model with respect to this type of dental issue is due to the fast growth of the
incisors and such a growth would not be expected to occur in the molars. There were no changes in
the bones (femur) from control and high-dose males and females.
The effect on teeth observed both by clinical inspection and as histopathology ﬁndings gives a strong
suspicion of ﬂuorosis. The aspect of ﬂuorosis has, however, not been discussed in the study report.
ADME data submitted by the applicant indicate that N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-
benzamide [FL-no: 16.119] is not extensively hydrolysed by liver microsomes in vitro. The only
metabolites that have been identiﬁed were those where the parent compound had been hydroxylated in
different positions on the cyclohexane ring (see Section 4 and Appendix D). Upon request further
information on stability of the N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide molecule [FL-no:
16.119] has been provided by industry, as well as results from analysis of the test substance and the
feed for free ﬂuoride (Flavouring Industry, 2015). Results indicate that N-(2-methylcyclohexyl)-
2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] is stable over time. Analysis of three manufactured
batches of the test substance showed some variation in ﬂuoride ion concentration between samples of
the same lot, but the average results were similar from lot-to-lot and the average detectable level of
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ﬂuoride ions was 0.7 mg/kg. No detectable amounts of ﬂuoride were found above the limit of
determination when the rat feed was analysed; results are reported as < 0.3 mg/kg free ﬂuoride ion in
feed. If the effect on teeth in the 90-day study is indeed ﬂuorosis, the source of ﬂuoride is not known.
The rat, in particular, has proved to be a good model for human dental ﬂuorosis, as the rat shows the
same disturbances at similar plasma levels as humans. However, rats require approximately 10 times
higher dosages of ﬂuoride than humans to achieve the same plasma levels. In general, ﬂuoride doses
that induce cellular changes in ameloblasts are at least two orders of magnitude higher than those that
induce mineralisation disturbances (Bronckers et al., 2009; Perumal et al., 2013).
Based on clinical observations of teeth, histopathology observations on ameloblasts and enamel and
dentin in teeth and results from clinical chemistry analysis, the NOAEL for N-(2-methylcyclohexyl)-
2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] that may be derived from the above detailed 90-day
study in rats is 750 mg/kg feed, corresponding to an estimated daily intake of 55 and 66 mg/kg bw
per day for males and females, respectively.
Repeated dose toxicity data are summarised in Table E.3 (Appendix E).
7.3. Developmental/reproductive toxicity studies
There are no developmental/reproductive toxicity studies for the candidate substance. The 90-day
study described in Section 7.2 included investigations of sperm motility, epididymal sperm count,
homogenisation-resistant spermatid count and sperm morphological development, no effects
attributable to the test substance were found. Similarly, there were no changes in mean oestrus cycle
length, number of oestrus cycles or any microscopic changes in uterus, vagina, ovaries, oviducts or
cervix in treated females (Bauter, 2013).
7.4. Genotoxicity
The candidate substance, N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119]
is reported to be negative in two Ames tests, with and without metabolic activation (Kirby, 2008).
In an in vivo study, N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119]
(purity > 98%) was reported negative in a micronucleus test in mouse bone marrow (Song, 2008). The
ﬂavouring substance and vehicle control were administered by oral gavage. Three dose levels were used
in the assay: 500, 1,000 and 2,000 mg/kg bw. Dimethyl sulfoxide (DMSO) was used as a vehicle control
and a single, oral, gavage dose of cyclophosphamide of 80 mg/kg bw as a positive control. Animals were
killed 24 and 48 h after dosing. A total of 2,000 polychromatic erythrocytes (PCE) per animal were
analysed for frequency of micronuclei. No reduction (more than 20% vs that of the vehicle control) in the
percentage of PCE was observed, in all but one treatment group. The decrease in PCE/normochromatic
erythrocytes (NCE) ratio by 21.1% in male mice at 1,000 mg/kg (48 h) appears an isolated observation
and not related to treatment. An autoradiography study performed in rats showed that after a single oral
dose treatment with [14C]-N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide to rats, radioactivity
was widely distributed in all tissues supporting systemic exposure (Appendix E).
Conclusion on genotoxicity:
Data on genotoxicity do not preclude the evaluation of the candidate substance [FL-no: 16.119]
through the Procedure.
Genotoxicity data are summarised in Tables E.1 and E.2 (Appendix E).
8. Conclusion
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (the CEF Panel) was asked to deliver a scientiﬁc opinion on
the implications for human health of a chemically deﬁned ﬂavouring substance used in or on foodstuffs
in the Member States. In particular, the Panel was requested to evaluate the ﬂavouring substance
N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] in the FGE.302, using the
Procedure as referred to in the Commission Regulation (EC) No 1565/2000. This ﬂavouring substance
belongs to chemical group 30, Annex I of the Commission Regulation (EC) No 1565/20003. The
ﬂavouring substance is listed in the Union List, which was adopted by Commission Regulation (EU)
No 872/20122 and its consecutive amendments. The current evaluation is applicable only for the use
of this substance as a ﬂavour modiﬁer.
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The candidate substance belongs to structural class III and it has not been reported to occur
naturally in food. It possesses two chiral centres. Information on the ratios of the diastereoisomers has
been provided (cis 20–40% and trans 60–80%). Information on the absolute conﬁgurations at the two
asymmetric centres is lacking.
Data on genotoxicity do not preclude the evaluation of the candidate substance [FL-no: 16.119]
through the Procedure.
According to the default MSDI approach, the candidate substance has an intake in Europe of 2.4
lg/capita per day, which is below the threshold of concern value for structural class III (90 lg/person
per day).
The results of studies on metabolism and pharmacokinetics do not allow to conclude that the
metabolites of the candidate substance are innocuous. Accordingly, the [FL-no: 16.119] is evaluated
via the B-side of the Procedure scheme.
A NOAEL of 55 mg/kg bw per day may be derived from a 90-day oral toxicity study providing an
adequate margin of safety of 1.4 9 106. Thus, it can be concluded that N-(2-methylcyclohexyl)-
2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] is not of safety concern at the estimated levels of
intake based on the MSDI approach.
In order to determine whether the conclusion for the candidate substance evaluated through the
Procedure can be applied to the material of commerce, it is necessary to consider the available
speciﬁcations. For the material of commerce, information on the proportion of enantiomers has to be
provided.
When the estimated intake was based on the mTAMDI, it amounted to 520 lg/person per day for
the candidate substance [FL-no: 16.119]. This intake is above the threshold of concern value for the
structural class III (90 lg/person per day). Therefore, according to standard practice used by the
Panel, more speciﬁc information on uses and use levels is required for the candidate substance.
The Panel noted that the candidate substance is polyﬂuorinated and therefore the substance or
breakdown products may be persistent in the environment.
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Abbreviations
ADME absorption, distribution, metabolism, elimination
CAS Chemical Abstract Service
CEF EFSA Scientiﬁc Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids
CoE Council of Europe
DMSO dimethyl sulfoxide
EFFA European Flavour and Fragrance Association
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GLP Good Laboratory Practice
HPLC high-performance liquid chromatography
ID identity
IOFI International Organization of the Flavour Industry
IR infrared spectroscopy
IS internal standard
JECFA The Joint FAO/WHO Expert Committee on Food Additives
LC–MS/MS liquid chromatography–tandem mass spectrometry
MS mass spectrometry
MSDI Maximised Survey-derived Daily Intake
mTAMDI modiﬁed Theoretical Added Maximum Daily Intake
NAD nicotinamide adenine dinucleotide
NADP nicotinamide adenine dinucleotide phosphate
NCE normochromatic erythrocytes
NMR nuclear magnetic resonance
NOAEL No Observed Adverse Effect Level
NTP National Toxicology Program
PCE polychromatic erythrocytes
SCF Scientiﬁc Committee on Food
TAMDI Theoretical Added Maximum Daily Intake
US FDA US Food and Drug Administration
WHO World Health Organization
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Appendix A – Procedure for the safety evaluation
The approach for a safety evaluation of chemically deﬁned ﬂavouring substances as referred to in
Commission Regulation (EC) No 1565/20003, named the ‘Procedure’, is shown in schematic form in
Figure A.1. The Procedure is based on the Opinion of the Scientiﬁc Committee on Food expressed on 2
December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995,
1996, 1997, 1999).
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in the
Procedure is the subdivision of ﬂavourings into three structural classes (I, II and III) for which
thresholds of concern (human exposure thresholds) have been speciﬁed. Exposures below these
thresholds are not considered to present a safety concern.
Class I contains ﬂavourings that have simple chemical structures and efﬁcient modes of
metabolism, which would suggest a low order of oral toxicity. Class II contains ﬂavourings that have
structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises
ﬂavourings that have structural features that permit no strong initial presumption of safety, or may
even suggest signiﬁcant toxicity (Cramer et al., 1978). The thresholds of concern for these structural
classes of 1,800, 540 or 90 lg/person per day, respectively, are derived from a large database
containing data on subchronic and chronic animal studies (JECFA, 1996).
In Step 1 of the Procedure, the ﬂavourings are assigned to one of the structural classes. The
further steps address the following questions:
• Can the ﬂavourings be predicted to be metabolised to innocuous products9 (Step 2)?
• Do their exposures exceed the threshold of concern for the structural class (Steps A3 and B3)?
• Are the ﬂavourings or their metabolites endogenous10 (Step A4)?
• Does a NOAEL exist on the ﬂavourings or on structurally related substances (Steps A5 and
B4)?
In addition to the data provided for the ﬂavouring substances to be evaluated (candidate
substances), toxicological background information available for compounds structurally related to the
candidate substances is considered (supporting substances), in order to assure that these data are
consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to ﬂavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on speciﬁc ﬂavourings warranted
such actions.
9 ‘Innocuous metabolic products’: Products that are known or readily predicted to be harmless to humans at the estimated
intakes of the ﬂavouring agent (JECFA, 1997).
10 ‘Endogenous substances’: Intermediary metabolites normally present in human tissues and ﬂuids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997).
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Appendix C – Use levels/mTAMDI
C.1. Normal and maximum use levels
For each of the 18 food categories (Table C.1) in which the candidate substances are used, ﬂavour
industry reports a ‘normal use level’ and a ‘maximum use level’.3 According to the ﬂavour industry, the
‘normal use’ is deﬁned as the average of reported usages and ‘maximum use’ is deﬁned as the
95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different
food categories have been extrapolated from ﬁgures derived from 12 model ﬂavouring substances
(EFFA, 2004).
The ‘normal and maximum use levels’ for the candidate substance are reported in Table C.3.
C.2. mTAMDI calculations
The method for calculation of modiﬁed Theoretical Added Maximum Daily Intake (mTAMDI) values is
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may
consume the amount of ﬂavourable foods and beverages listed in Table C.2. These consumption
estimates are then multiplied by the reported use levels in the different food categories and summed up.
Table C.1: Food categories according to Commission Regulation (EC) No 1565/20003
Food category Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (including mushrooms & fungi, roots & tubers, pulses and
legumes), and nuts & seeds
05.0 Confectionery
06.0 Cereals and cereal products, including ﬂours & starches from roots & tubers,
pulses & legumes, excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and ﬁsh products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products, etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic (‘soft’) beverages, excluding dairy products
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods that could not
be placed in categories 01.0–15.0
Table C.2: Estimated amount of ﬂavourable foods, beverages, and exceptions assumed to be
consumed per person per day (SCF, 1995)
Class of product category Intake estimate (g/day)
Beverages (non-alcoholic) 324.0
Foods 133.4
Exception a: Candy, confectionery 27.0
Exception b: Condiments, seasonings 20.0
Exception c: Alcoholic beverages 20.0
Exception d: Soups, savouries 20.0
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum)
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The mTAMDI calculations are based on the normal use levels reported by industry. The seven food
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as
outlined in Commission Regulation (EC) No 1565/20003 and reported by the ﬂavour industry in the
following way (see Table C.4):
• Beverages (SCF, 1995) correspond to food category 14.1
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or
16
• Exception a (SCF, 1995) corresponds to food category 5 and 11
• Exception b (SCF, 1995) corresponds to food category 15
• Exception c (SCF, 1995) corresponds to food category 14.2
• Exception d (SCF, 1995) corresponds to food category 12
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum.
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Appendix D – Metabolism
D.1. Absorption, distribution and elimination
A single oral dose of 50 mg/kg of [14C]-N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide
(14C incorporated on the carbonyl group) (Figure D.1) was administered to male and female Sprague–
Dawley rats and the tissue distribution of radioactivity was investigated using the technique of whole-
body autoradiography. Pairs of rats (one male and one female) were killed at 1, 3, 9, 24 and 72 h
post-administration and sagittal sections were obtained at six levels through the carcasses, freeze-
dried and exposed to phosphor-imaging plates for 3 days. The distribution of radioactivity was
assessed qualitatively, by visual inspection of the images. Following oral administration, radioactivity
(representing N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide and/or its metabolites) was
absorbed and widely distributed into all tissues throughout the animal body. Tissue radioactivity
concentrations were greatest during 1–3 h after dosing, with the majority of tissues containing
concentrations similar to that observed in the blood. The greatest concentrations were associated with
the excretory organs (liver, kidney, gastrointestinal tract and urinary bladder). The lowest
concentrations of radioactivity occurred in the lens of the eye. By 72 h after dosing (the ﬁnal sacriﬁce
time), radioactivity concentrations had declined but were still present (at low levels) in the
gastrointestinal tract, liver, kidney, lung, blood, skin, tongue, and the harderian and lacrimal glands.
Apart from those tissues which are gender speciﬁc, there were no sex-related differences in the
distribution of [14C]-N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide and/or its metabolites
(Penketh, 2009).
D.2. Metabolism
In vitro metabolism study in rat liver microsomes
In an in vitro metabolism study, 1, 3, 30 and 100 lM of [14C]-N-(2-methylcyclohexyl)-2,3,4,5,6-
pentaﬂuoro-benzamide were incubated (at 37°C) with rat liver microsomes (0.5 mg/mL) for 0, 10, 30,
60 and 120 min. At the end of the required incubation time, the reactions were stopped by addition of
acetonitrile. The samples were centrifuged and the supernatants were submitted for analysis. Analysis
of the treated samples by high-performance liquid chromatography (HPLC) showed that after 120 min
of incubation [14C]-N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide was almost completely
metabolised to form up to 16 different metabolites (Kirby, 2009).
In a mass spectrometry (MS) analysis of the 30 lM and 100 lM samples (120 min incubation), only
hydroxylated metabolites of N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide were identiﬁed.
In all cases, it was the methyl cyclohexyl ring that underwent the hydroxylation step (see Figure D.2).
Hydroxylation did not occur at the nitrogen or at C1 in the cyclohexyl ring (Kirby, 2009).
F
F
F
F
14C
N
H
O
F
Figure D.1: The radiolabeled [14C]-N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide
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In vitro metabolism study in isolated rat hepatocytes
An in vitro study was conducted at Xenotech LLC Labs in 2015 (IFF, 2016) to determine the
metabolic stability of N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide [FL-no: 16.119] using a
suspension culture of cryopreserved rat hepatocytes. After 0, 15, 30, 60, 90 and 180 min of incubation
(1 lM of substrate, 1 million cells per mL), the reactions were stopped by the addition of stop reagent
(i.e. acetonitrile containing an internal standard). Additional incubations were carried out with the
hepatocytes by replacing the test article with 7-ethoxycoumarin (positive control substrate) to conﬁrm
metabolic competency of the cells. The samples were centrifuged and the supernatant fractions analysed
by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Analysis was determined for the test
article in each incubation solution. Results were determined by comparison of the analyte/internal
standard (IS) peak-area ratios over the time course of the experiment and expressed as ‘% Parent
Remaining’. Zero-time incubations served as the ‘100%-remaining’ values. In vitro half-life (min) and
in vitro intrinsic clearance values (lL/min per 106 cells) were estimated.
The hepatocyte cell viability ranged from ~ 70% to ~ 51% over the course of the 3-h incubation
and was determined to be within acceptable limits for this assay. The positive control data conﬁrmed
the metabolic competency of the rat hepatocyte test system. Under the conditions of this test system,
N-(2-methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide was rapidly cleared (3 h) by the cultured
hepatocytes with an estimated half-life and in vitro clearance rate for the parent test article to be
18 min and 39 lL/min per million cells, respectively.
The above described results indicate that the test material is rapidly metabolised in the liver.
D.3. Summary and conclusion
The kinetics of the candidate substance have been investigated in microsomes, in hepatocytes and
in vivo by autoradiography (14C incorporated on the carbonyl group) after oral administration to rats.
Results from the in vitro study on metabolism in rat liver microsomes show that N-(2-
methylcyclohexyl)-2,3,4,5,6-pentaﬂuoro-benzamide is readily hydroxylated by liver microsomes in vitro.
These metabolites may be anticipated to be easily conjugated and excreted.
Also in hepatocyte incubations, rapid metabolism of the candidate ﬂavouring substance was
observed but no attempt was made to identify the biotransformation products. Next to hydroxylation,
hydrolysis of the amide bond might occur which would result in formation of 2-methyl-cyclohexylamine
and pentaﬂuorobenzoic acid. However, there are no data to support this. In addition, there is no
information whether deﬂuorination in vivo might occur but from the molecular structure this seems
unlikely.
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Figure D.2: Interpretation of metabolite structure based on MS and chemical considerations
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